Takeda and Evotec Enter Gene-Therapy Research Pact
Takeda and Evotec GT, an Austria-based subsidiary of Evotec, a Hamburg, Germany-based drug- discovery and development company, have entered into a long-term research alliance to support Takeda’s research-stage gene-therapy discovery programs.
Evotec GT is part of Evotec’s integrated modality-agnostic drug discovery platform that combines all activities involved with the discovery, development, and manufacturing of therapeutics along the value chain.
Under the alliance, Evotec will support multiple Takeda programs targeting conditions aligned with Takeda’s four core therapeutic areas: oncology, rare diseases, neuroscience, and gastroenterology.
No financial details of the agreement were disclosed.